Listen Live
Donate
 on air
Schedule

KCRW

Read & Explore

  • News
  • Entertainment
  • Food
  • Culture
  • Events

Listen

  • Live Radio
  • Music
  • Podcasts
  • Full Schedule

Information

  • About
  • Careers
  • Help / FAQ
  • Newsletters
  • Contact

Support

  • Become a Member
  • Become a VIP
  • Ways to Give
  • Shop
  • Member Perks

Become a Member

Donate to KCRW to support this cultural hub for music discovery, in-depth journalism, community storytelling, and free events. You'll become a KCRW Member and get a year of exclusive benefits.

DonateGive Monthly

Copyright 2025 KCRW. All rights reserved.

Report a Bug|Privacy Policy|Terms of Service|
Cookie Policy
|FCC Public Files

Back to Press Play with Madeleine Brand

Press Play with Madeleine Brand

Safe COVID vaccine for kids? Stanford researchers are working to make it happen in Pfizer study

Stanford started a study this week to find the safe and effective COVID-19 vaccine dosage for kids under age 12.

  • rss
  • Share
KCRW placeholderBy Michell Eloy • Apr 16, 2021 • 5m Listen

On April 15, everyone in California ages 16 and older became eligible for a COVID-19 vaccine. Right now, there’s no approved pediatric vaccine, even as kids across the state have returned to in-person classrooms.

That’s why this week, the medical school at Stanford started a study, where they’re administering Pfizer shots to kids as young as 2. It’s a big piece missing in the quest to achieve a new normal.

“Kids make up 20% of the population, so we’ll definitely need to have them involved to reach herd immunity. It might take a little bit of time, but being careful is the best that we can do,” says clinical trials specialist Dr. Jenna Bollyky, who’s working on the Pfizer study at Stanford.

Bollyky says step one is finding a safe dosage for kids. Adults who received the Pfizer vaccine get 30 micrograms. This study is starting with three micrograms for older children.

“The phase one study is working to give children under the age of 12 the vaccine and find the right dose to make sure it’s safe and efficacious,” she says.

Parents enroll their kids in this study, and Bollyky says her patients are adventurous, curious, and willing to participate.

  • KCRW placeholder

    Michell Eloy

    Line Editor, Press Play

  • KCRW placeholder

    Sarah Sweeney

    Vice President of Talk Programming, KCRW

  • KCRW placeholder

    Angie Perrin

    Producer, Press Play

  • KCRW placeholder

    Michell Eloy

    Line Editor, Press Play

  • KCRW placeholder

    Dr. Jenna Bollyky

    internal medicine/clinical trials specialist working on the Stanford study

    NewsCoronavirusHealth & WellnessScience
Back to Press Play with Madeleine Brand